Skip to content

ADHD Core

Evidence-Based Updates & Advocacy

home
  • Research
  • Patient Advocacy
  • News
  • Parenting
  • ADHD Heroes
  • About Dr. Purnoor | Founder of ADHDCore
  • Why I Built ADHDCore
  • Medical Disclaimer
  • Editorial Policy
  • Research
  • Patient Advocacy
  • News
  • Parenting
  • ADHD Heroes
  • About Dr. Purnoor | Founder of ADHDCore
  • Why I Built ADHDCore
  • Medical Disclaimer
  • Editorial Policy

Tag: ADHD drug development

Prescription bottle labeled Centanafadine beside an FDA review sign and a July 2026 calendar with July 24 circled, representing the FDA review timeline for the investigational ADHD medication.
News

Centanafadine for ADHD: FDA Review Update, Decision Pending

Posted onApril 19, 2026April 19, 2026

Centanafadine for ADHD: FDA Review Timeline, Phase 3 Data and What It Could Mean ADHD treatment · drug development · FDA review A new class… Continue Reading Centanafadine for ADHD: FDA Review Update, Decision Pending

Compliance

  • Privacy Policy
  • Editorial Policy
  • Medical Disclaimer
  • Terms and Conditions
© 2026 ADHD Core Privacy Policy Powered by WordPress Theme by Design Lab
Exit mobile version
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.